Drug intelligence / Profile preview

RA-003 (Red Arrow Therapeutics)

Development stage: Preclinical
Lead developer: Red Arrow Therapeutics
Modality: Nanoparticles → Drug Delivery Systems, Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

RA-003 is an investigational therapeutic being developed by Red Arrow Therapeutics for the treatment of solid tumors. It is based on the company's proprietary Nanopolymer Cytokine Micelle (NCM) platform, which aims to improve the therapeutic index of cytokines by enabling targeted delivery to tumor tissues while reducing systemic exposure. As of early 2024, the specific cytokine payload and molecular targets for RA-003 have not been disclosed by the developer, and the program remains in the discovery and preclinical stages of development.

Beyond the preview

Go deeper on RA-003 (Red Arrow Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA-003 (Red Arrow Therapeutics).

Explore the full profile